How Alzheimer's Disease Develops in the Brain
Alzheimer's disease begins silently decades before any symptoms appear. Here is what actually happens inside the brain — from rogue proteins to dying neurons — and why it remains so hard to treat.
A Silent Epidemic
More than 55 million people worldwide live with dementia, and Alzheimer's disease accounts for roughly 60–70% of those cases, according to the World Health Organization. By 2050, that figure is projected to surpass 150 million as populations age globally. Yet despite its devastating scale, many people remain unclear on what actually happens inside the brain — why memories fade, why personalities change, and why the disease has proved so difficult to treat.
The answer lies in the slow, decades-long buildup of two rogue proteins.
The Two Culprit Proteins
Alzheimer's disease is defined by the accumulation of two abnormal proteins: beta-amyloid and tau. Together, they disrupt neural communication, kill brain cells, and cause the brain to physically shrink over time.
Beta-Amyloid Plaques
Beta-amyloid is a fragment naturally produced when a larger protein — the amyloid precursor protein — is broken down. In a healthy brain, these fragments are cleared away as waste. In Alzheimer's, they clump together between neurons into sticky deposits called plaques. The most toxic form, beta-amyloid 42, is especially prone to aggregation. These plaques interfere with communication between neurons and trigger inflammatory responses from the brain's own immune cells, compounding the damage.
Tau Tangles
Tau protein normally acts as scaffolding inside neurons, stabilizing structures called microtubules that transport nutrients and electrical signals throughout the cell. In Alzheimer's, tau undergoes chemical changes — becoming hyperphosphorylated — that cause it to detach from microtubules and twist into tangled pairs of filaments. These neurofibrillary tangles collapse the cell's internal transport system. Without the ability to move essential materials, neurons eventually die.
Research published in JAMA Neurology describes amyloid as the "trigger" and tau as the "bullet": amyloid accumulation appears to activate tau's toxic transformation, and the two then reinforce each other in a destructive feedback loop.
A Disease That Starts Decades Before Symptoms
One of Alzheimer's most striking — and clinically frustrating — features is its prolonged silent phase. According to the National Institute on Aging, damage to the brain likely begins 10 to 20 years before any memory problems appear. During this preclinical stage, amyloid plaques accumulate quietly while cognitive function appears entirely normal.
Only once tau tangles begin spreading — particularly into the hippocampus, the brain's primary memory hub — do recognizable symptoms emerge. The disease then progresses in a characteristic pattern:
- Early stage: The entorhinal cortex and hippocampus are attacked first, causing the short-term memory lapses that are typically the earliest warning sign.
- Middle stage: Damage spreads into the cerebral cortex, impairing language, reasoning, and judgment. Behavioral changes become pronounced.
- Late stage: Widespread neuronal death leaves individuals unable to communicate or perform basic self-care tasks.
Why Treatment Is So Hard
This prolonged hidden phase has long frustrated researchers. By the time a diagnosis is confirmed, substantial neuronal damage has already occurred. Early drugs targeting amyloid — built on the theory that clearing plaques should halt the disease — produced disappointing results in trials, partly because they were tested in patients whose disease had already advanced significantly.
Recent breakthroughs have offered guarded optimism. The FDA has approved two monoclonal antibodies — lecanemab (Leqembi) and donanemab (Kisunla) — that actively clear amyloid from the brain in people with early-stage Alzheimer's. According to the Alzheimer's Association, lecanemab is the first treatment to address the underlying biology of the disease and demonstrably slow its course. Clinical trials show both drugs meaningfully reduce cognitive decline — though they do not reverse damage already done.
Researchers are now testing whether these drugs can work even earlier, in the preclinical phase, to prevent symptoms from ever appearing. Two major studies — the AHEAD trial and TRAILBLAZER-ALZ 3 — are recruiting participants with amyloid buildup but no symptoms, in hopes of intervening before the cascade of damage begins.
The Bigger Picture
The Alzheimer's field is shifting its focus from symptom management to disease modification — and ultimately, to prevention. Scientists are also investigating the roles of genetics (particularly the APOE4 gene variant), chronic inflammation, cardiovascular health, sleep quality, and the brain's glymphatic waste-clearance system as factors that accelerate or delay onset.
Alzheimer's remains one of medicine's most complex challenges. But a clearer picture of how the disease unfolds — protein by protein, neuron by neuron — is bringing scientists meaningfully closer to stopping it before it starts.
